Central sleep apnea

Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy

Retrieved on: 
木曜日, 5月 23, 2024
Risk, Obesity, ESS, ResMed, Ageing, SAN, ATS, Woman, ASV, Therapy, University of California, ASX, Plan, Health care, LVEF, Coronary artery disease, Sleep, Grenoble Alpes University, Literature review, Natural language processing, Conference, CSA, Circulatory system, Meta-analysis, BMI, AHI, Clinical trial, NIV, Obstructive sleep apnea, Qualitative Research (journal), Comorbidity, Depression, NYHA, Sleep disorder, Hospital, Research, OSA, COPD, Central sleep apnea, PAP, Patient, Education, Qualitative, RMD, Prevalence, University, Overalls, Mortality, Death, Abstract, Economy, Adaptation, Quality of life, Pharmaceutical industry

SAN DIEGO, May 23, 2024 (GLOBE NEWSWIRE) -- A number of accomplished medical and scientific experts presented critical new research on sleep conditions and their effect on cardiovascular health at the American Thoracic Society International Conference. The ResMed-supported research provided new insights into the effectiveness of PAP therapy in treating sleep-disordered breathing and its associated clinical benefits. The studies were among 26 supported by ResMed (NYSE: RMD, ASX: RMD) in collaboration with leading scientists including Michael Arzt, MD, Universitätsklinikum Regensburg, Germany; Jean-Louis Pépin, MD, Grenoble Alpes University, France; Atul Malhotra, MD, University of California, San Diego; and Holger Woehrle, Ulm Lung Centre, Germany.

Key Points: 
  • The ResMed-supported research provided new insights into the effectiveness of PAP therapy in treating sleep-disordered breathing and its associated clinical benefits.
  • Several studies demonstrated findings showing continued effectiveness of PAP therapies for patients with sleep disorder conditions like obstructive sleep apnea.
  • This finding demonstrates a correlation between the use of PAP therapy and a reduction in use of healthcare resources.
  • Two studies evaluated the effects of Adaptive Servo-Ventilation (ASV) therapy in two populations, patients with TE-CSA and patients on long-term opioid therapy.

$23.1 Billion Sleep Apnea Devices Market, Industry Trends and Global Forecasts 2024-2035 - ResearchAndMarkets.com

Retrieved on: 
火曜日, 5月 14, 2024
Medical Devices, Health, Obstructive sleep apnea, ResMed, Ventilation, USD, Interest, Prevalence, Diagnosis, Overalls, Ageing, Non-invasive ventilation, Administration, Sleep apnea, Research, Growth, LivaNova, Hub, Woman, Central sleep apnea, CPAP, Polysomnography, APAP, Pharmaceutical industry

The growth in the sleep apnea devices market share over the next decade is likely to be the result of anticipated increase in patient population and rise in the demand for sleep apnea devices for sleep apnea treatment.

Key Points: 
  • The growth in the sleep apnea devices market share over the next decade is likely to be the result of anticipated increase in patient population and rise in the demand for sleep apnea devices for sleep apnea treatment.
  • The global sleep apnea diagnostic devices market is categorized into polysomnography devices and home sleep apnea testing devices.
  • The market report features an extensive study of the current market landscape, sleep apnea devices market share, market size, market analysis, market forecast and future opportunities for the sleep apnea companies involved in the development of sleep apnea medical devices and sleep apnea drugs.
  • Sleep Apnea Devices Market Analysis: Sleep Apnea Therapeutic Devices Hold Majority Market Share
    The global sleep apnea devices market is estimated to be worth USD 13.5 billion in 2024.

Late-breaking Analysis From the remedē® System Pivotal Trial Suggests Favorable Outcomes for Heart Failure (HF) Patients With Central Sleep Apnea Receiving Phrenic Nerve Stimulation

Retrieved on: 
月曜日, 5月 13, 2024
Medical Devices, Health, Technology, Other Technology, Software, General Health, Patient, HF, Heart failure, Asahi Kasei, ESC, CSA, Hospital, Division, Mortality, Central sleep apnea, Ohio State University, Pharmaceutical industry

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that a new analysis of data from the remedē® System Pivotal Trial suggests favorable outcomes for heart failure (HF) patients with central sleep apnea (CSA).

Key Points: 
  • ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that a new analysis of data from the remedē® System Pivotal Trial suggests favorable outcomes for heart failure (HF) patients with central sleep apnea (CSA).
  • The analysis was performed post-hoc using a hierarchical endpoint comprised of mortality, HF hospitalization, and health status.
  • The presented analysis re-evaluates the pivotal trial data using a win ratio to compare heart failure patients with central sleep apnea when treated with phrenic nerve stimulation (treatment group) versus patients with untreated CSA (control group).
  • “The new analysis also highlights the importance of screening for central sleep apnea in patients with heart failure so effective therapies like phrenic nerve stimulation can be offered.”

Sleep Apnea Devices Market, Industry Trends and Global Forecasts, 2035

Retrieved on: 
金曜日, 3月 15, 2024
Diagnosis, ResMed, Non-invasive ventilation, Sleep apnea, CPAP, Growth, Prevalence, APAP, LivaNova, Obstructive sleep apnea, Polysomnography, Ageing, Ventilation, Research, Overalls, Central sleep apnea, Woman, Hub, Interest, USD, Administration, Pharmaceutical industry

The growth in the sleep apnea devices market share over the next decade is likely to be the result of anticipated increase in patient population and rise in the demand for sleep apnea devices for sleep apnea treatment.

Key Points: 
  • The growth in the sleep apnea devices market share over the next decade is likely to be the result of anticipated increase in patient population and rise in the demand for sleep apnea devices for sleep apnea treatment.
  • The global sleep apnea diagnostic devices market is categorized into polysomnography devices and home sleep apnea testing devices.
  • The market report features an extensive study of the current market landscape, sleep apnea devices market share, market size, market analysis, market forecast and future opportunities for the sleep apnea companies involved in the development of sleep apnea medical devices and sleep apnea drugs.
  • Sleep Apnea Devices Market Analysis: Sleep Apnea Therapeutic Devices Hold Majority Market Share
    The global sleep apnea devices market is estimated to be worth USD 13.5 billion in 2024.

ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea

Retrieved on: 
月曜日, 2月 12, 2024
RMD, SAN, Inhalation, Central sleep apnea, ASV, MyAir, CPAP, Sleep apnea, Culture, Part, Sleep, Obstructive sleep apnea, Exhalation, Respiratory rate, Digital technology, ResMed, ASX, IPAP, PAP, Patient, Ventilation, Software, Pressure, Medical device

AirCurve 11 devices are built on ResMed’s market-leading AirSense 11 platform and enhance the suite of offerings available for healthcare providers and clinicians when determining the best care for sleep apnea patients.

Key Points: 
  • AirCurve 11 devices are built on ResMed’s market-leading AirSense 11 platform and enhance the suite of offerings available for healthcare providers and clinicians when determining the best care for sleep apnea patients.
  • This design allows the device to align more closely with the patient’s natural breathing pattern.
  • myAir3, a patient engagement app that tracks sleep and therapy progress with a daily sleep score, now with support for bilevel patients.
  • AirView, a secure, cloud-based system that helps providers monitor and manage patients’ therapy remotely, enabling an informed pathway to optimal care.

ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea

Retrieved on: 
月曜日, 1月 8, 2024
Policy, Splint (medicine), DDS, Obstructive sleep apnea, Treatment, UHC, Research, CPAP, MBA, Congress, Clinical trial, Cureus, Central sleep apnea, OAT, OSA, Patient, Data, AHI, Sleep apnea

PLEASANTON, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA ) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, welcomes the adoption of UnitedHealthcare’s updated medical policy (#2024T0525NN) for Obstructive and Central Sleep Apnea, effective March 1, 2024.

Key Points: 
  • PLEASANTON, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA ) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, welcomes the adoption of UnitedHealthcare’s updated medical policy (#2024T0525NN) for Obstructive and Central Sleep Apnea, effective March 1, 2024.
  • Specifically, the policy states, “Failure of adequate trial of Oral Appliance therapy,” as the new medical policy of UHC.
  • “I am pleased to see this policy update acknowledging the role of oral appliances in the continuum of care for Obstructive Sleep Apnea,” commented Edward T. Sall, MD, DDS, MBA.
  • Modern oral appliances are safe, effective, comfortable, and easy for the patient to insert, remove and keep clean.

Project Sleep Launches the Sleep Helpline™ to Provide Free and Personalized Support for People Facing Sleep Issues and Sleep Disorders

Retrieved on: 
水曜日, 12月 6, 2023
Sleep, JD, Kleine–Levin syndrome, DSM-IV codes, REM, Narcolepsy, Sleep disorder, Patient, LOS, Obstructive sleep apnea, Idiopathic hypersomnia, Uncertainty, Sleep-related breathing disorder, Central sleep apnea, Eastern Time Zone, Caregiver, University, Upper airway resistance syndrome, Parasomnia, Diagnosis, Social, Doctor of Philosophy, Sleepwalking, Restless legs syndrome, Non-24-hour sleep–wake disorder, Pharmaceutical industry, Nursing

LOS ANGELES, Dec. 6, 2023 /PRNewswire/ -- Project Sleep, a nonprofit dedicated to raising awareness of sleep health, sleep equity, and sleep disorders, is thrilled to announce the official launch of the Sleep Helpline™, a new, professionally-staffed national helpline providing timely and trusted resources to help individuals navigate sleep issues and sleep disorders at every step of the journey.

Key Points: 
  • "An estimated 50-70 million Americans live with a chronic sleep disorder, yet the majority are undiagnosed," said Julie Flygare , JD, President & CEO of Project Sleep.
  • "We know that the path to finding accurate sleep disorder diagnosis, treatment, and support is often long, lonely, and inefficient.
  • This is why the new Sleep Helpline will meet people where they are in moments of uncertainty, to provide free and personalized one-to-one support and resources."
  • Special thanks to Jazz Pharmaceuticals and Harmony Biosciences for generously providing sponsorship funding to support the development of Project Sleep's new Sleep Helpline to support millions of people facing sleep issues and sleep disorders.

Sleep apnea implants market size to grow by USD 2,82,442.79 thousand from 2022 to 2027|North America held 41% of the global market in 2022 - Technavio

Retrieved on: 
金曜日, 11月 17, 2023
Sleep, Brain, Safety, Sample, Organization, Prevalence, Incidence, European Medicines Agency, ROW, Risk, EMA, Sleep apnea, Heart, Obstructive sleep apnea, USD, Central sleep apnea, OSA, Health, Challenge, Humidifier, Geography, Mask, Growth, Hospital, Headscarf, Blood pressure, Pharmaceutical industry, Medical device, COVID-19

Many non-profit organizations, key providers, and government organizations conduct awareness campaigns about sleep apnea and sleep apnea implantable devices.

Key Points: 
  • Many non-profit organizations, key providers, and government organizations conduct awareness campaigns about sleep apnea and sleep apnea implantable devices.
  • The sleep apnea implants market extensively covers market segmentation by indication (central sleep apnea and obstructive sleep apnea), end-user (ambulatory surgical centers, hospitals, and others), and geography (North America, Europe, Asia, and the Rest of World (ROW)).
  • For central sleep apnea, sleep apnea implants are the most commonly used treatment.
  • Growth of the sleep apnea implants market across North America, Europe, Asia, and the Rest of World (ROW)
    Comprehensive analysis of factors that will challenge the growth of sleep apnea implants market companies.

Florida Physician ACO, Millennium Physician Group, Taps REMware for Sleep Apnea Testing Services

Retrieved on: 
月曜日, 10月 9, 2023
Technology, Medical Devices, Diabetes, Fitness & Nutrition, Health Technology, Software, Other Health, Alternative Medicine, Health, Cardiovascular disease, Hypertension, Sleep medicine, Obstructive sleep apnea, Disease, Type 2 diabetes, Central sleep apnea, Immune system, Depression, Sleep, Sleep apnea, ER, Patient, Pharmaceutical industry, Hospital, MD

Millennium Physician Group , an independent physician group practicing in Florida, Texas and North Carolina, announced they have selected sleep technology company REMware™ to provide home sleep apnea testing services through their more than 750 health care providers.

Key Points: 
  • Millennium Physician Group , an independent physician group practicing in Florida, Texas and North Carolina, announced they have selected sleep technology company REMware™ to provide home sleep apnea testing services through their more than 750 health care providers.
  • REMware is the developer of a home sleep testing patented process, called DreamClear™, that simplifies and accelerates the entire diagnostic process to meet the escalating demand to detect and treat undiagnosed sleep apnea.
  • “Approximately 42% of Americans have one or more chronic diseases that have a strong comorbid association to undiagnosed or untreated obstructive sleep apnea,” said REMware CEO Arun Ramabadran.
  • “Addressing sleep apnea improves value-based metrics at a lower cost, especially related to expensive health issues such as cardiovascular disease, hypertension, Type 2 diabetes and depression.

Side Health Partners with REMware To Provide Home Sleep Testing to Chronic Disease Patients

Retrieved on: 
木曜日, 6月 1, 2023
Hardware, Health Technology, Other Health, Technology, Finance, Practice Management, Managed Care, Professional Services, Medical Devices, Seniors, Fitness & Nutrition, Dental, Family, Consumer, Health, Hypertension, Cardiovascular disease, Sleep apnea, Central sleep apnea, Patient, Diabetes, Obstructive sleep apnea, Risk, Education, Pharmaceutical industry, Nursing

Sleep technology company REMware™ has signed an agreement with Side Health, a national chronic care management company, to provide sleep apnea testing services to meet the growing demand to detect and treat undiagnosed sleep apnea among their patients.

Key Points: 
  • Sleep technology company REMware™ has signed an agreement with Side Health, a national chronic care management company, to provide sleep apnea testing services to meet the growing demand to detect and treat undiagnosed sleep apnea among their patients.
  • REMware’s home sleep testing patented process, called DreamClear™, simplifies and accelerates the entire diagnostic process for Side Health’s patients and providers, according to REMware CEO Arun Ramabadran.
  • Side Health specializes in fully-integrated care, including comprehensive remote patient monitoring, to help patients with multiple medical conditions better manage their care.
  • “More than 18 million Americans have undiagnosed sleep apnea, which is a serious condition linked to a wide array of health issues, including cardiovascular disease, hypertension and diabetes.